Overweight or Obesity
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (15)
Total enrollment: 4,016 patients across 15 trials
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
A Study of BGM0504 Injection in Participants with Obesity or Overweight
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
National Survey of Young Adult Nutrition
Berries, Inflammation, and Gut Microbiome
Related Jobs in Metabolic Diseases
Seattle Territory Business Leader
Phoenix North Territory Business Leader
Portland Clinical Diabetes Specialist
Manager, GxP Quality Systems
Clinical Diabetes Specialist - Tampa
Clinical Diabetes Specialist - Washington DC
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.